Group 2A: Imaging

Thursday, Oct 5
2:00 pm – 3:30 pm Eastern Time (US/New York)

Poster #1:

Pre-Operative MRI for Screening Digital Breast Tomosynthesis-Detected Invasive Lobular Carcinoma: Who Benefits Most?

Poster author Manisha Bahl, M.D. is also the scientist for this session

Poster #2:

Contrast-Enhanced Mammography (CEM) Compared to Breast Magnetic Resonance (MRI) In the Management of Breast Lobular Neoplasia: A New Scenario in Facing the Diagnosis of an Insidious Disease

Mentor: Laurie Hutcheson, M.S.

Laurie Hutcheson is an invasive lobular breast cancer patient advocate & Executive Director of the Lobular Breast Cancer Alliance (LBCA)

Laurie has been a leader in health care program development and management for over 40 years. Her experience includes executive roles in Massachusetts health and human services agencies, in behavioral health provider organizations and managing her own consulting business. Laurie joined LBCA as a volunteer following her diagnosis and treatment for invasive lobular carcinoma (ILC) in 2018. In May 2020, in lieu of retirement, she took over as LBCA’s executive director. Laurie is committed to working collaboratively with patient advocates, scientists, and clinicians in the U.S. and globally to raise awareness about ILC and to promote vitally needed ILC research.

Laurie is a graduate of the National Breast Cancer Coalition’s Project LEAD. She is also an active research advocate in the Dana Farber/Harvard Cancer Center Breast Cancer Advocate group, and Komen Advocates in Science (AIS), and is on the board of the National Breast Cancer Coalition. She is a peer counselor with After Breast Cancer Diagnosis (ABCD), and a member of the MBC Alliance and of the European Lobular Breast Cancer Consortium. She received her master’s degree from the Harvard TH Chan School of Public Health.

Twitter: @lobularBCA

Scientist: Manisha Bahl, M.D.

Manisha Bahl, MD, MPH, FSBI, is the Breast Imaging Division Quality Director at the Massachusetts General Hospital, an Associate Professor of Radiology at Harvard Medical School, and a Fellow of the Society of Breast Imaging. Dr. Bahl is an NIH-funded physician-scientist with research interests in the application of artificial intelligence to support more targeted and precise treatment options for women with ductal carcinoma in situ and high-risk breast lesions. She has won numerous awards for her research, including the American Roentgen Ray Society President’s Award. Dr. Bahl is an Associate Editor for Radiology and Radiology: AI. She has given more than 100 invited lectures and is an award-winning teacher and mentor.